Dicerna Pharmaceuticals, Inc. DRNA
Apr 24, 2025, 3:47 PM EDT
52-week range unavailable
- Market cap
- 2.98B
- Revenue (ttm)
- 192.85M
- Profit margin
- -64.53%
- Shares out
- 77.91M
- Forward P/E
- -19.11
- Volume
- 5.54M
- Open
- 38.21
- Previous close
- 38.22
- Day's range
- 38.21 – 38.24
- Beta
- 0.79
- Analysts
- Hold
- Price target
- 38.25 (+0.1%)
- Earnings date
- Nov 9, 2021
2Y +16.80 (+78.43%)
Key statistics
- Enterprise value
- 2.48B
- PEG ratio
- 0.00
- Price / sales
- 15.44
- Price / book
- 27.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 28.80%
- Free cash flow
- -45.58M
- Total cash
- 565.51M
- Total debt
- 64.42M
- Return on equity
- -95.22%
- Short % of float
- 6.39%
- 50-day average
- 31.45
- 200-day average
- 28.97
Analyst view
Consensus: hold
- Strong buy1
- Buy2
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 9, 2021
Expected Nov 9, 2021. Consensus EPS estimate -0.54.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2021 | Sep 1, 2021 | -0.41 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | 0.51 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | -0.28 | — | — | — |
| Feb 25, 2021 | Dec 1, 2020 | 0.11 | — | — | — |
| Nov 5, 2020 | Sep 1, 2020 | -0.17 | — | — | — |
| Aug 6, 2020 | Jun 1, 2020 | 0.21 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2021 | Chardan Capital | down | Buy | Neutral |
| Nov 19, 2021 | RBC Capital | down | Outperform | Sector Perform |
| Nov 18, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 11, 2021 | Goldman Sachs | down | Buy | Neutral |
| Aug 10, 2021 | Chardan Capital | main | — | Buy |
| Aug 10, 2021 | HC Wainwright & Co. | main | — | Buy |
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dicerna.com
News
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition - Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna 
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna 
Shares of RNAi Drug Companies Pop After Novo Lays Out $3.3 Billion for Dicerna 
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Dicerna Pharmaceuticals, Inc. - DRNA 
Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion 
SHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc. 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo Nordisk 
Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%
Your note
Sign in to keep a note on DRNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARADHYE SHREERAM | Officer | Conversion of Exercise of derivative security | Dec 14, 2021 | 6,973 |
| BROWN BOB D | Officer | Conversion of Exercise of derivative security | Dec 14, 2021 | 2,367 |
| BUCHI J. KEVIN CPA | Director | Conversion of Exercise of derivative security | Jun 2, 2021 | 4,666 |
| CIAPPENELLI ROBERT D | Officer | Conversion of Exercise of derivative security | Dec 14, 2021 | 14,813 |
| FAMBROUGH DOUGLAS M | Chief Executive Officer | Conversion of Exercise of derivative security | Dec 14, 2021 | 231,431 |
| KOZIN MARC D | Director | Purchase | Aug 9, 2021 | 11,333 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 9.70% | 7,582,396 | 152.86M | Sep 29, 2021 |
| Blackrock Inc. | 7.38% | 5,763,585 | 116.19M | Sep 29, 2021 |
| State Street Corporation | 4.97% | 3,886,181 | 78.35M | Sep 29, 2021 |
| Vanguard Group, Inc. (The) | 4.74% | 3,707,210 | 74.74M | Sep 29, 2021 |
| Bain Capital Life Sciences Investors, LLC | 3.94% | 3,080,237 | 62.10M | Sep 29, 2021 |
| Price (T.Rowe) Associates Inc | 3.43% | 2,682,596 | 54.08M | Sep 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.23% | 2,526,829 | 50.94M | Sep 29, 2021 |
| Vanguard Total Stock Market Index Fund | 2.51% | 1,963,234 | 39.58M | Sep 29, 2021 |
| iShares Russell 2000 ETF | 2.07% | 1,618,173 | 33.67M | Oct 30, 2021 |
| Price (T.Rowe) New Horizons Fund | 1.43% | 1,117,136 | 22.52M | Sep 29, 2021 |
| Vanguard Explorer Fund, Inc. | 1.42% | 1,105,726 | 41.48M | Jul 30, 2021 |
| Vanguard Extended Market Index Fund | 1.21% | 944,801 | 19.05M | Sep 29, 2021 |